<DOC>
	<DOC>NCT02141139</DOC>
	<brief_summary>It is increasingly recognized the NSAIDS (nonsteroidal antiinflammatory drug) might prevent the several cancers. In breast cancer, the role of NSAIDS (nonsteroidal antiinflammatory drug) has been suggested.However, there was no consistent results. surgery is main cause of inflammation for cancer patients. Therefore, we want to know the association between prevention of perioperative inflammation with NSAIDS and breast cancer outcomes.</brief_summary>
	<brief_title>Perioperative Inflammation and Breast Cancer Outcome</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Breast cancer patients who took the surgery underlying medical disease (major heart disease, lung disease, coagulopathy) major psychologic disease (major depression, schizophrenia, manic disorder) pregnancy rheumatic disease patients</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Perioperative Period</keyword>
</DOC>